Literature DB >> 1520109

Ofloxacin vs tobramycin for the treatment of external ocular infection. Ofloxacin Study Group II.

A Gwon1.   

Abstract

A multicenter, double-masked, randomized clinical investigation was conducted comparing 0.3% ofloxacin and 0.3% tobramycin for topical treatment of external ocular infection. One drop (1.35 micrograms) of either test solution was instilled six times daily for 2 days and thereafter four times daily for the next 8 days. At the day 3 to 5 follow-up examination, the severity of signs and symptoms based on a clinical summary score of 10 key variables was reduced from baseline values significantly (P less than .05) more with ofloxacin (-6.4 +/- 4.37; mean +/- SD) than with tobramycin (-4.78 +/- 3.13); by day 11, the difference between the groups was no longer significant. At days 3 to 5 and day 11 examinations, clinical, microbiologic, and overall improvement rates were similar, with no significant differences seen between the groups. Ofloxacin was found as effective, safe, and comfortable as tobramycin in patients with external ocular infection and may provide earlier symptom relief.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1520109     DOI: 10.1001/archopht.1992.01080210052022

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  8 in total

Review 1.  Interventions for chronic blepharitis.

Authors:  Kristina Lindsley; Sueko Matsumura; Elham Hatef; Esen K Akpek
Journal:  Cochrane Database Syst Rev       Date:  2012-05-16

2.  Safety and tolerability of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis: data from six clinical and phase I safety studies.

Authors:  Timothy L Comstock; Michael R Paterno; Heleen H Decory; Dale W Usner
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

Review 3.  Treatment of ocular infections with topical antibacterials.

Authors:  J P Leeming
Journal:  Clin Pharmacokinet       Date:  1999-11       Impact factor: 6.447

4.  3-day treatment with azithromycin 1.5% eye drops versus 7-day treatment with tobramycin 0.3% for purulent bacterial conjunctivitis: multicentre, randomised and controlled trial in adults and children.

Authors:  Isabelle Cochereau; Amel Meddeb-Ouertani; Moncef Khairallah; Abdelouahed Amraoui; Khalid Zaghloul; Mihai Pop; Laurent Delval; Pascale Pouliquen; Radhika Tandon; Prashant Garg; Pablo Goldschmidt; Tristan Bourcier
Journal:  Br J Ophthalmol       Date:  2006-10-18       Impact factor: 4.638

5.  Acute infectious conjunctivitis in childhood.

Authors:  R Chawla; J D Kellner; W F Astle
Journal:  Paediatr Child Health       Date:  2001-07       Impact factor: 2.253

Review 6.  Pharmacokinetic considerations in the treatment of bacterial keratitis.

Authors:  M C Callegan; R J O'Callaghan; J M Hill
Journal:  Clin Pharmacokinet       Date:  1994-08       Impact factor: 6.447

7.  Delivery of antibiotics to the eye using a positively charged polysaccharide as vehicle.

Authors:  O Felt; V Baeyens; P Buri; R Gurny
Journal:  AAPS PharmSci       Date:  2001

8.  Bacterial conjunctivitis.

Authors:  Cindy Hutnik; Mohammad H Mohammad-Shahi
Journal:  Clin Ophthalmol       Date:  2010-12-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.